Gene suppression by tristetraprolin and release by the p38 pathway.
about
MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decayThe ARE-dependent mRNA-destabilizing activity of BRF1 is regulated by protein kinase BRegulation and localization of endogenous human tristetraprolinDecreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathwayTristetraprolin inhibits poly(A)-tail synthesis in nuclear mRNA that contains AU-rich elements by interacting with poly(A)-binding protein nuclear 1Expression and purification of recombinant tristetraprolin that can bind to tumor necrosis factor-alpha mRNA and serve as a substrate for mitogen-activated protein kinasesRNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signalingInhibition of tristetraprolin deadenylation by poly(A) binding protein.Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesisPhosphorylation site analysis of the anti-inflammatory and mRNA-destabilizing protein tristetraprolin.Identification of a major phosphopeptide in human tristetraprolin by phosphopeptide mapping and mass spectrometry.Myocardial knockdown of mRNA-stabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice.Expression, purification, and biochemical characterization of the antiinflammatory tristetraprolin: a zinc-dependent mRNA binding protein affected by posttranslational modifications.Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic proteinMitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich elementPARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.The anti-inflammatory carbazole, LCY-2-CHO, inhibits lipopolysaccharide-induced inflammatory mediator expression through inhibition of the p38 mitogen-activated protein kinase signaling pathway in macrophages.Novel phosphorylation-dependent ubiquitination of tristetraprolin by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) and tumor necrosis factor receptor-associated factor 2 (TRAF2).A GFP-based assay for rapid screening of compounds affecting ARE-dependent mRNA turnoverDominant Suppression of Inflammation via Targeted Mutation of the mRNA Destabilizing Protein Tristetraprolin.Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance.The role of tristetraprolin in cancer and inflammation.Mutant tristetraprolin: a potent inhibitor of malignant glioma cell growth.Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action.Phosphorylation of recombinant tristetraprolin in vitroTIS11 family proteins and their roles in posttranscriptional gene regulation.mRNA-binding protein ZFP36 is expressed in atherosclerotic lesions and reduces inflammation in aortic endothelial cellsInvolvement of p38-βTrCP-Tristetraprolin-TNFα axis in radiation pneumonitis.Cerebral preconditioning using cortical application of hypertonic salt solutions: upregulation of mRNAs encoding inhibitors of inflammation.Suppression of lipopolysaccharide-stimulated tumor necrosis factor-alpha production by adiponectin is mediated by transcriptional and post-transcriptional mechanisms.Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region.Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways.A knock-in tristetraprolin (TTP) zinc finger point mutation in mice: Comparison with complete TTP deficiency.
P2860
Q24316111-AD1E5134-6782-4DEB-8113-83B2DCA80CD2Q24558903-C932D634-73C0-4E3E-8AF0-FF70311749B7Q24805049-E99A1ECD-1662-4995-BBE5-62A2984803E8Q28350388-4E9B7218-8556-4989-B363-E6861B491E42Q28506698-0397C41F-D29B-49CA-B72E-882332401771Q28609864-4F2A493D-9C47-444F-81BA-A1E201ECF3C3Q30434431-AD4DB4FF-6906-4DA7-97B4-C29A3F09F761Q30438742-533AE021-6338-4F76-9E96-9179F98D1DF3Q33226407-343D901E-586F-4440-B2FA-959A47ECA6B9Q33309340-FCDD9F8B-0152-4127-971C-88366E6F1116Q33881972-3196C43F-D127-45D5-B2E1-DA8EFA73A8FFQ33919479-E4E6B435-FC78-4EAE-8833-52B4899F8CCFQ34314339-1858C10E-59B7-467E-9DFD-506D2C6700AEQ34314352-065CCA39-254A-4014-9D34-E9390689D3D1Q34519852-8E3F6AF5-6F09-4FBC-A50C-5DC6D1F43450Q34636901-B38F706F-2FA8-463B-A96C-DD155E1E8067Q35046269-E789CA94-1746-4904-873E-81D6B914DD96Q35516227-C2567792-B9B3-461D-9084-B938AE90452DQ35618681-C55C4BEB-598B-425E-A8E3-DD416F7E8AC9Q35757055-F8F03047-9083-4E95-9388-6FB5544E4FA3Q35951508-001DE5C3-27F1-452C-A972-9565A6296124Q36290434-CC6192C8-5734-417A-8563-BAE81F39A67EQ36920373-A08E0C67-A00E-4CD0-85EF-9787E93030E2Q37119721-2B7C15B7-789D-4827-9532-27532E089021Q37172238-55EB9BE8-7C92-4B76-ADBE-33CB5608D93FQ37292351-7A4BB6FE-10FD-4913-AF0D-C5E1C5B8AF5EQ37352012-B1BDBEEF-AD45-4823-97B6-838EF329BC7EQ38761499-7034621D-7165-46DE-8E34-0C0CFED25682Q39669203-E168606B-C9D0-4EB7-8673-4295043E2701Q39954096-ABFA234B-2DCD-45C5-9488-02C78B6B2704Q42279904-12AD4534-C84B-4F84-BCA7-E98604AD0519Q43241254-4E033DAC-1AA6-4A0E-918A-930264659630Q47332424-DA4C0B5A-60CF-496F-9CB0-902F9786B893
P2860
Gene suppression by tristetraprolin and release by the p38 pathway.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Gene suppression by tristetraprolin and release by the p38 pathway.
@en
type
label
Gene suppression by tristetraprolin and release by the p38 pathway.
@en
prefLabel
Gene suppression by tristetraprolin and release by the p38 pathway.
@en
P2093
P2860
P1476
Gene suppression by tristetraprolin and release by the p38 pathway.
@en
P2093
Brauchle MA
Di Padova F
P2860
P304
P356
10.1152/AJPLUNG.2001.281.2.L499
P577
2001-08-01T00:00:00Z